GB9411292D0 - Pharmaceuticals compositions - Google Patents

Pharmaceuticals compositions

Info

Publication number
GB9411292D0
GB9411292D0 GB9411292A GB9411292A GB9411292D0 GB 9411292 D0 GB9411292 D0 GB 9411292D0 GB 9411292 A GB9411292 A GB 9411292A GB 9411292 A GB9411292 A GB 9411292A GB 9411292 D0 GB9411292 D0 GB 9411292D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceuticals compositions
pharmaceuticals
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9411292A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to GB9411292A priority Critical patent/GB9411292D0/en
Publication of GB9411292D0 publication Critical patent/GB9411292D0/en
Priority to ZA954469A priority patent/ZA954469B/en
Priority to IL11399295A priority patent/IL113992A0/en
Priority to AU27874/95A priority patent/AU2787495A/en
Priority to CA002192218A priority patent/CA2192218A1/en
Priority to JP8500007A priority patent/JPH10500695A/en
Priority to EP95923229A priority patent/EP0767672A1/en
Priority to PCT/EP1995/002125 priority patent/WO1995033475A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB9411292A 1994-06-06 1994-06-06 Pharmaceuticals compositions Pending GB9411292D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB9411292A GB9411292D0 (en) 1994-06-06 1994-06-06 Pharmaceuticals compositions
ZA954469A ZA954469B (en) 1994-06-06 1995-05-31 Pharmaceutical compositions
IL11399295A IL113992A0 (en) 1994-06-06 1995-06-02 Use of copolymer-1
AU27874/95A AU2787495A (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
CA002192218A CA2192218A1 (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
JP8500007A JPH10500695A (en) 1994-06-06 1995-06-05 Use of copolymer-1 for preparing a medicament for treating optic neuritis
EP95923229A EP0767672A1 (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
PCT/EP1995/002125 WO1995033475A1 (en) 1994-06-06 1995-06-05 Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9411292A GB9411292D0 (en) 1994-06-06 1994-06-06 Pharmaceuticals compositions

Publications (1)

Publication Number Publication Date
GB9411292D0 true GB9411292D0 (en) 1994-07-27

Family

ID=10756253

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9411292A Pending GB9411292D0 (en) 1994-06-06 1994-06-06 Pharmaceuticals compositions

Country Status (8)

Country Link
EP (1) EP0767672A1 (en)
JP (1) JPH10500695A (en)
AU (1) AU2787495A (en)
CA (1) CA2192218A1 (en)
GB (1) GB9411292D0 (en)
IL (1) IL113992A0 (en)
WO (1) WO1995033475A1 (en)
ZA (1) ZA954469B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093828A1 (en) * 2000-06-05 2001-12-13 Teva Pharmaceuticals Industries, Ltd. The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
JP5297653B2 (en) 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト Manufacturing method of glatiramer

Also Published As

Publication number Publication date
JPH10500695A (en) 1998-01-20
EP0767672A1 (en) 1997-04-16
AU2787495A (en) 1996-01-04
CA2192218A1 (en) 1995-12-14
IL113992A0 (en) 1995-10-31
WO1995033475A1 (en) 1995-12-14
ZA954469B (en) 1996-01-24

Similar Documents

Publication Publication Date Title
GB9417524D0 (en) Pharmaceutical compositions
ZA957233B (en) Topically-effective compositions
EG20929A (en) Cleasing compositions
GB9408545D0 (en) Compositions
HU9503199D0 (en) Pharmaceutical basic compositions
IL113329A0 (en) Benzamide-containing pharmaceutical compositions
GB9418609D0 (en) Pharmaceutical compositions
GB9411292D0 (en) Pharmaceuticals compositions
GB9409543D0 (en) Compositions
GB9502770D0 (en) Amine-curable compositions
ZA954709B (en) Mineral-fiber compositions
GB2290299B (en) Anti-lubricant compositions
ZA959081B (en) Pharmaceutical compositions
GB9406835D0 (en) Pharmaceutical compositions
GB2295825B (en) Pharmaceutical compositions
GB9416768D0 (en) Compositions
EP0705632A3 (en) 2-Methylpropenyl-terminated polyisobutylene-polydimethyl-siloxane compositions
HU9400096D0 (en) Pharmaceutical compositions
HU9601821D0 (en) Pharmaceutical compositions
GB9416767D0 (en) Compositions
GB9707483D0 (en) Pharmaceutical compositions
GB9404457D0 (en) Pharmaceutical compositions
GB9407235D0 (en) Pharmaceutical compositions
GB9405879D0 (en) Pharmaceutical compositions
GB9413072D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
730A Proceeding under section 30 patents act 1977